There were “terrible flaws” in Moderna’s COVID-19 vaccine clinical trials — and the U.S. Food and Drug Administration (FDA) knew it, according to Alexandra Latypova, a former pharmaceutical industry executive who reviewed nearly 700 pages of documents Moderna submitted to the FDA as part of its application process.
Latypova, who has 25 years of experience in pharmaceutical research and development, started a number of successful companies — primarily focused on creating and reviewing clinical trials.
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr